

Formulary Updates to Denver Health Medicaid Choice (DHMC) and Child Health Plan Plus (CHP+) Plans

DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs during the year. If DHMC/CHP+ removes drugs from the formulary, or adds a restriction to an existing formulary drug, such as prior authorization, quantity limits and/or step therapy, [and/or moves a drug to a higher cost-sharing tier], DHMC/CHP+ will notify you of the change at least 10 days before the date that the change becomes effective. If the Food and Drug Administration (FDA) deems a drug on the formulary to be unsafe, or the drug's manufacturer removes the drug from the market, DHMC/CHP+ will immediately remove the drug from the formulary.

The table below outlines previous and/or recent changes to the formulary. The newest updates are highlighted in yellow. For questions or if you would like more information related to these changes please call the DHMC/CHP+ Pharmacy Services Department at 303-602-2070 or 877-357-0963.

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New | Restrictions | Effective |
|---------------------------|------------------------------------|-------------------|-------------------|--------|--------------|------------|
| | | Reason for Change | Alternative Drug | Tier | | Date |
| FreeStyle Libre 3 Sensors | New Addition | New Addition | N/A | Tier 2 | LA, QL | 07/01/2022 |
| Dexcom G6 Receiver, | New Addition | New Addition | FreeStyle Libre 3 | Tier 4 | LA, QL, ST | 07/01/2022 |
| Transmitter and Sensors | | | Sensors | | | |
| Molnupiravir Capsules | New Addition | Regulatory | N/A | Tier 1 | QL | 07/01/2022 |
| | | Requirement | | | | |
| Paxlovid Tablets | New Addition | Regulatory | N/A | Tier 1 | QL | 07/01/2022 |
| | | Requirement | | | | |
| Fluticasone HFA Inhalers | New Generic for Flovent HFA; | New Generic | N/A | Tier 2 | LA, QL | 07/01/2022 |
| | Tier Change from Tier 4 to Tier 2 | | | | | |
| Fluticasone/Vilanterol | New Generic for Breo Ellipta; Tier | New Generic | Fluticasone/ | Tier 2 | LA, QL, ST | 07/01/2022 |
| Inhalers | Change from Tier 4 to Tier 2 | | Salmeterol and | | | |

FORMULARY ABBREVIATIONS (Explanations can be found on the website in the DHMC/CHP+ Formulary and Pharmaceutical Management Procedures) LA = Limited Access (must be filled at DH Pharmacy or PA Required); PA = Prior Authorization; QL = Quantity Limit; ST = Step Therapy

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective Date |
|----------------------------|-----------------------------------|-------------------|-------------------|-------------|--------------|-------------------|
| | | | Budesonide/ | | | |
| | | | Formoterol | | | |
| Lacosamide Tablets and | New Generic for Vimpat; Tier | New Generic | Two of the | Tier 2 | LA, QL, ST | 07/01/2022 |
| Oral Solution | Change from Tier 4 to Tier 2 | | following: | | | |
| | | | Carbamazepine, | | | |
| | | | Divalproex sodium | | | |
| | | | or valproic acid, | | | |
| | | | Felbamate, | | | |
| | | | Gabapentin, | | | |
| | | | Lamotrigine, | | | |
| | | | Levetiracetam, | | | |
| | | | Oxcarbazepine, | | | |
| | | | Phenobarbital, | | | |
| | | | Phenytoin, | | | |
| | | | Pregabalin | | | |
| | | | (Lyrica) <i>,</i> | | | |
| | | | Topiramate, | | | |
| | | | Zonisamide | | | |
| Insulin Glargine Vials and | New Generic for Lantus and | New Generic | N/A | Tier 1 | QL | 07/01/2022 |
| Pens | Lantus Solostar; Tier Change from | | | | | |
| | Tier 3 to Tier 1 | | | | | |
| Vilazodone Tablets | New Generic for Viibryd; Tier | New Generic | Three of the | Tier 2 | LA, QL, ST | 07/01/2022 |
| | Change from Tier 4 to Tier 2 | | following: | | | |
| | | | bupropion, | | | |
| | | | citalopram, | | | |
| | | | desvenlafaxine, | | | |
| | | | duloxetine, | | | |
| | | | escitalopram, | | | |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective Date |
|---------------------------|---------------------------------|-----------------------|------------------|-------------|--------------|-------------------|
| | | | fluoxetine, | | | |
| | | | fluvoxamine, | | | |
| | | | mirtazapine, | | | |
| | | | paroxetine, | | | |
| | | | sertraline, | | | |
| | | | venlafaxine | | | |
| Fetzima Capsules | Prior Authorization Restriction | Clinical Reevaluation | Two of the | N/A | LA, QL, ST | 04/01/2022 |
| | Removed; Step Therapy | | following: | | | |
| | Restriction Added | | Desvenlafaxine | | | |
| | | | Succinate, | | | |
| | | | Duloxetine, | | | |
| | | | Venlafaxine | | | |
| | | | Extended-Release | | | |
| Vraylar Capsules | Prior Authorization Restriction | Clinical Reevaluation | Two of the | N/A | LA, QL, ST | 04/01/2022 |
| | Removed; Step Therapy | | following: | | | |
| | Restriction Added | | Aripiprazole, | | | |
| | | | Clozapine, | | | |
| | | | Lamotrigine, | | | |
| | | | Lithium, | | | |
| | | | Olanzapine, | | | |
| | | | Quetiapine, | | | |
| | | | Risperidone, | | | |
| | | | Ziprasidone | | | |
| Apretude Injection | New Addition | Regulatory | N/A | Tier 4 | LA | 04/01/2022 |
| | | Requirement | | | | |
| Lokelma Packets | New Addition | New Addition | N/A | Tier 4 | LA, QL | 04/01/2022 |
| Estradiol Vaginal Tablets | New Addition | New Addition | N/A | Tier 1 | QL | 04/01/2022 |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective Date |
|---|---|-----------------------------------|--|-------------|--------------|-------------------|
| Imvexxy Vaginal Inserts | New Addition | New Addition | Estradiol Vaginal Cream and Estradiol Vaginal Tablets | Tier 4 | LA, QL, ST | 04/01/2022 |
| Phexxi Vaginal Gel | New Addition | New Addition | N/A | Tier 4 | LA, QL | 04/01/2022 |
| Brimonidine/Timolol Eye Drops | New Generic for Combigan; Tier Change from Tier 4 to Tier 2 | New Generic | N/A | Tier 2 | LA | 04/01/2022 |
| Cyclosporine Eye Drops | New Generic for Restasis; Tier Change from Tier 4 to Tier 2 | New Generic | N/A | Tier 2 | LA, QL | 04/01/2022 |
| Naloxone Nasal Spray | New Generic for Narcan Nasal Spray; Tier Change from Tier 3 to Tier 1 | New Generic | N/A | Tier 1 | QL | 04/01/2022 |
| Glycopyrrolate Oral Solution | New Generic for Cuvposa; Tier Change from Tier 4 to Tier 2 | New Generic | N/A | Tier 2 | LA, QL, PA | 04/01/2022 |
| Dexlansoprazole Capsules | New Generic for Dexilant; Tier Change from Tier 4 to Tier 2 | New Generic | N/A | Tier 2 | LA, QL, ST | 04/01/2022 |
| Calcipotriene Solution, Cream and Ointment | Step Therapy Restriction Removed | Clinical and Cost Reevaluation | N/A | N/A | LA, QL | 01/01/2022 |
| Invokana Tablets | Step Therapy Restriction Removed | Clinical and Cost Reevaluation | N/A | N/A | LA, QL | 01/01/2022 |
| Jardiance Tablets | Step Therapy Restriction Removed | Clinical and Cost Reevaluation | N/A | N/A | LA, QL | 01/01/2022 |
| Trintellix Tablets | Prior Authorization Restriction Removed; Step Therapy Restriction Added | Clinical Reevaluation | Three of the following: bupropion, citalopram, desvenlafaxine, | | LA, QL, ST | 01/01/2022 |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective Date |
|-----------------------|---------------------------------|-----------------------|------------------|-------------|--------------|-------------------|
| | | | duloxetine, | | | |
| | | | escitalopram, | | | |
| | | | fluoxetine, | | | |
| | | | fluvoxamine, | | | |
| | | | mirtazapine, | | | |
| | | | paroxetine, | | | |
| | | | sertraline, | | | |
| | | | venlafaxine | | | |
| Viibryd Tablets | Prior Authorization Restriction | Clinical Reevaluation | Three of the | | LA, QL, ST | 01/01/2022 |
| | Removed; Step Therapy | | following: | | | |
| | Restriction Added | | bupropion, | | | |
| | | | citalopram, | | | |
| | | | desvenlafaxine, | | | |
| | | | duloxetine, | | | |
| | | | escitalopram, | | | |
| | | | fluoxetine, | | | |
| | | | fluvoxamine, | | | |
| | | | mirtazapine, | | | |
| | | | paroxetine, | | | |
| | | | sertraline, | | | |
| | | | venlafaxine | | | |
| Paliperidone Tablets | Prior Authorization Restriction | Clinical Reevaluation | Aripiprazole, | N/A | LA, QL, ST | 01/01/2022 |
| | Removed; Step Therapy | | Clozapine, | | | |
| | Restriction Added | | Olanzapine, | | | |
| | | | Quetiapine, | | | |
| | | | Risperidone, or | | | |
| | | | Ziprasidone | | | |
| Latuda Tablets | Prior Authorization Restriction | Clinical Reevaluation | Two of the | N/A | LA, QL, ST | 01/01/2022 |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective Date |
|--------------------------|--------------------------------|-------------------|--------------------|-------------|--------------|-------------------|
| | Removed; Step Therapy | | following: | | | |
| | Restriction Added | | Aripiprazole, | | | |
| | | | Clozapine, | | | |
| | | | Lamotrigine, | | | |
| | | | Lithium, | | | |
| | | | Olanzapine, | | | |
| | | | Quetiapine, | | | |
| | | | Risperidone, | | | |
| | | | Ziprasidone | | | |
| Azelaic Acid Gel | New Addition | New Addition | N/A | Tier 1 | QL | 10/01/2021 |
| Linezolid Tablets | New Addition | New Addition | N/A | Tier 1 | QL | 10/01/2021 |
| Nebivolol Tablets | New Generic for Bystolic; Tier | New Generic | Two of the | Tier 2 | LA, QL, ST | 10/01/2021 |
| | Change from Tier 4 to Tier 2 | | Following: | | | |
| | | | Atenolol, | | | |
| | | | Carvedilol, | | | |
| | | | Labetalol, | | | |
| | | | Metoprolol, | | | |
| | | | Nadolol, Pindolol, | | | |
| | | | Propranolol, | | | |
| | | | Sotalol | | | |
| Colchicine Tablets | Step Therapy Restriction | Clinical and Cost | N/A | N/A | LA, QL | 10/01/2021 |
| | Removed | Reevaluation | | | | |
| Desvenlafaxine Succinate | Step Therapy Restriction | Clinical and Cost | N/A | N/A | LA, QL | 10/01/2021 |
| Tablets | Removed | Reevaluation | | | | |
| Tacrolimus Ointment | Step Therapy Restriction | Clinical and Cost | N/A | N/A | LA, QL | 10/01/2021 |
| | Removed | Reevaluation | | | | |
| Eliquis Tablets | Step Therapy Restriction | Clinical and Cost | N/A | N/A | LA, QL | 10/01/2021 |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective Date |
|-----------------------|---------------------------------|-----------------------|------------------|-------------|--------------|-------------------|
| | Removed | Reevaluation | | | | |
| Repatha Syringes, | Prior Authorization Restriction | Clinical Reevaluation | Two of the | N/A | LA, QL, ST | 10/01/021 |
| SureClick Pens and | Removed; Step Therapy | | following: | | | |
| Pushtronex On-Body | Restriction Added | | Atorvastatin, | | | |
| Infusor | | | Lovastatin, | | | |
| | | | Pravastatin, | | | |
| | | | Rosuvastatin, | | | |
| | | | Simvastatin | | | |
| Varenicline Tablets | New Generic for Chantix | New Generic | N/A | N/A | QL | 10/01/2021 |
| Motegrity Tablets | New Addition | New Addition | Lubiprostone | Tier 4 | LA, QL, ST | 10/01/2021 |
| Trokendi XR Capsules | New Addition | New Addition | Topiramate ER | Tier 4 | LA, QL, ST | 10/01/2021 |
| | | | (generic for | | | |
| | | | Qudexy XR) | | | |
| Droxia Capsules | New Addition | New Addition | Hydroxurea 500 | Tier 4 | LA, QL, ST | 10/01/2021 |
| | | | mg (generic for | | | |
| | | | Hydrea) | | | |
| Dificid Tablets and | New Addition | New Addition | N/A | Tier 4 | LA, QL | 10/01/2021 |
| Suspension | | | | | | |
| Tresiba Vials and | New Addition | New Addition | Lantus and | Tier 4 | LA, QL, ST | 07/01/2021 |
| FlexTouch Pens | | | Levemir | | | |
| Repatha Syringes, | New Addition | New Addition | N/A | Tier 4 | LA, PA | 07/01/2021 |
| SureClick Pens and | | | | | | |
| Pushtronex On-Body | | | | | | |
| Infusor | | | | | | |
| Etravirine Tablets | New Generic for Intelence; Tier | New Generic | N/A | Tier 2 | LA | 07/01/2021 |
| | Change from Tier 5 to Tier 2 | | | | | |
| Lopinavir/Ritonavir | New Generic for Kaletra; Tier | New Generic | N/A | Tier 2 | LA, QL | 07/01/2021 |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective Date |
|--------------------------|--|---------------------------------------|---|-------------|--------------|-------------------|
| Tablets | Change from Tier 5 to Tier 2 | | | | | |
| Rufinamide Tablets | New Generic for Banzel; Tier Change from Tier 4 to Tier 2 | New Generic | Lamotrigine, Topiramate and Clobazam | Tier 2 | LA, QL, ST | 07/01/2021 |
| Progesterone Capsules | Quantity Limit Increased | Clinical and Cost Reevaluation | N/A | N/A | QL | 07/01/2021 |
| Scopolamine Patches | New Addition | New Addition | N/A | Tier 2 | LA, QL | 04/01/2021 |
| Divigel Packets | New Addition | New Addition | Estradiol Tablets or Patches | Tier 4 | LA, QL, ST | 04/01/2021 |
| Briviact Tablets | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 04/01/2021 |
| Zolmitriptan Nasal Spray | New Generic for Zomig Nasal Spray | New Generic | N/A | Tier 1 | QL | 04/01/2021 |
| Lubiprostone Capsules | New Generic for Amitiza; Prior Authorization Restriction Removed; Tier Change from Tier 4 to Tier 2 | New Generic; Clinical Reevaluation | N/A | Tier 2 | LA, QL | 04/01/2021 |
| Linzess Capsules | Prior Authorization Restriction Removed; Step Therapy Restriction Added | Clinical Reevaluation | Lubiprostone | N/A | LA, QL, ST | 04/01/2021 |
| Cambia Packets | Prior Authorization Restriction Removed; Step Therapy Restriction Added | Clinical Reevaluation | Two of the Following: Eletriptan, Rizatriptan, Sumatriptan, Zolmitriptan | N/A | LA, QL, ST | 04/01/2021 |
| Biktarvy Tablets | Step Therapy Restriction Removed | Clinical Reevaluation | N/A | N/A | LA, QL | 04/01/2021 |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective Date |
|--------------------------|-----------------------|-------------------|--------------------|-------------|--------------|-------------------|
| Buprenorphine Patches | New Addition | New Addition | N/A | Tier 1 | QL | 04/01/2021 |
| Prasugrel Tablets | New Addition | New Addition | N/A | Tier 1 | | 04/01/2021 |
| Cinacalcet Tablets | New Addition | New Addition | N/A | Tier 4 | LA, PA | 04/01/2021 |
| Dimethyl Fumarate | New Addition | New Addition | N/A | Tier 4 | LA, PA | 04/01/2021 |
| Capsules | | | | | | |
| Bystolic Tablets | New Addition | New Addition | Two of the | Tier 4 | LA, QL, ST | 04/01/2021 |
| | | | Following: | | | |
| | | | Atenolol, | | | |
| | | | Carvedilol, | | | |
| | | | Labetalol, | | | |
| | | | Metoprolol, | | | |
| | | | Nadolol, Pindolol, | | | |
| | | | Propranolol, | | | |
| | | | Sotalol | | | |
| Esterified Estrogen/ | Deletion | Regulatory | N/A | N/A | | 04/01/2021 |
| Methyltestosterone | | Requirement | | | | |
| Tablets | | | | | | |
| Hydrocortisone Acetate | Deletion | Regulatory | N/A | N/A | | 04/01/2021 |
| Suppositories | | Requirement | | | | |
| Dichloralphenazone/ | Deletion | Regulatory | N/A | N/A | | 04/01/2021 |
| Isometheptene/ | | Requirement | | | | |
| Acetaminophen Capsules | | | | | | |
| Hydrocortisone/ | Deletion | Regulatory | N/A | N/A | | 04/01/2021 |
| Pramoxine Rectal Cream | | Requirement | | | | |
| Potassium Citrate/Citric | Deletion | Regulatory | N/A | N/A | | 04/01/2021 |
| Acid Packets | | Requirement | | | | |
| Phenobarbital/ | Deletion | Regulatory | N/A | N/A | | 04/01/2021 |

| | | | | New | Destrictions | Effective |
|---------------------------|------------------------------------|-----------------------|------------------|--------|--------------|------------|
| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | Tier | Restrictions | Date |
| Hyoscyamine/Atropine/ | | Requirement | | | | |
| Scopolamine Tablets | | | | | | |
| Polyethylene glycol 3350/ | New Addition | New Addition | N/A | Tier 1 | | 01/01/2021 |
| Sodium sulfate/Sodium | | | | | | |
| chloride/Potassium | | | | | | |
| chloride/Ascorbic acid/ | | | | | | |
| Sodium ascorbate | | | | | | |
| (MoviPrep) Bowel | | | | | | |
| Preparation Kit | | | | | | |
| Coartem Tablets | New Addition | New Addition | N/A | Tier 3 | QL | 01/01/2021 |
| Imatinib Tablets | New Addition | New Addition | N/A | Tier 4 | LA, PA | 01/01/2021 |
| Tasigna Capsules | New Addition | New Addition | N/A | Tier 5 | LA, PA | 01/01/2021 |
| Budesonide/Formoterol | Tier Change from Tier 2 to Tier 1; | Clinical Reevaluation | N/A | Tier 1 | QL | 01/01/2021 |
| Inhalers | Limited Access Restriction | | | | | |
| | Removed; Quantity Limit | | | | | |
| | Increased | | | | | |
| Efavirenz/Emtricitabine/ | New Generic for Atripla | New Generic | N/A | Tier 2 | LA | 01/01/2021 |
| Tenofovir Disoproxil | | | | | | |
| Fumarate Tablets | | | | | | |
| Emtricitabine/ | New Generic for Truvada | New Generic | N/A | Tier 2 | LA | 01/01/2021 |
| Tenofovir Disoproxil | | | | | | |
| Fumarate Tablets | | | | | | |
| Fosfomycin Packets | New Generic for Monurol | New Generic | N/A | Tier 1 | QL | 01/01/2021 |
| Levothyroxine Capsules | New Generic for Tirosint | New Generic | Levothyroxine | Tier 2 | LA, QL, ST | 01/01/2021 |
| | | | Tablets | | | |
| Rufinamide Suspension | New Generic for Banzel | New Generic | Lamotrigine, | Tier 2 | LA, QL, ST | 01/01/2021 |
| | | | Topiramate and | | | |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New | Restrictions | Effective |
|------------------------|---------------------------------|-------------------|------------------|--------|--------------|------------|
| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | Tier | Restrictions | Date |
| | | | Clobazam | | | |
| Tolvaptan Tablets | New Generic for Jynarque | New Generic | N/A | Tier 4 | LA, QL, PA | 01/01/2021 |
| Alvesco Inhalers | New Addition | New Addition | N/A | Tier 3 | QL | 10/01/2020 |
| Lumigan Eye Drops | New Addition | New Addition | Latanoprost Eye | Tier 4 | LA, QL, ST | 10/01/2020 |
| | | | Drops and | | | |
| | | | Travoprost Eye | | | |
| | | | Drops | | | |
| Vyzulta Eye Drops | New Addition | New Addition | Latanoprost Eye | Tier 4 | LA, QL, ST | 10/01/2020 |
| | | | Drops and | | | |
| | | | Travoprost Eye | | | |
| | | | Drops | | | |
| Zejula Capsules | New Addition | New Addition | N/A | Tier 5 | LA, QL, PA | 10/01/2020 |
| Tymlos Injection | New Addition | New Addition | N/A | Tier 5 | LA, QL, PA | 10/01/2020 |
| Forteo Injection | New Addition | New Addition | N/A | Tier 5 | LA, QL, PA | 10/01/2020 |
| Emtricitabine 200 mg | New Generic for Emtriva 200 mg | New Generic | N/A | Tier 4 | LA | 10/01/2020 |
| Capsule | Capsules | | | | | |
| Ciprofloxacin/ | New Generic for Ciprodex Ear | New Generic | N/A | Tier 1 | | 10/01/2020 |
| Dexamethasone Ear | Drops | | | | | |
| Drops | | | | | | |
| FreeStyle Libre Reader | Prior Authorization Restriction | Clinical and Cost | N/A | N/A | LA, QL | 10/01/2020 |
| and Sensor | Removed | Reevaluation | | | | |
| Nurtec ODT Orally- | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 07/01/2020 |
| Disintegrating Tablets | | | | | | |
| Ubrelvy Tablets | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 07/01/2020 |
| Reyvow Tablets | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 07/01/2020 |
| Bunavail Buccal Film | New Addition | Regulatory | N/A | Tier 1 | QL | 07/01/2020 |
| | | Requirement | | | | |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective Date |
|---------------------------|-----------------------------------|-------------------|-------------------|-------------|--------------|-------------------|
| Zubsolv Sublingual Tablet | New Addition | Regulatory | N/A | Tier 1 | QL | 07/01/2020 |
| | | Requirement | | | | |
| Sublocade Injection | New Addition | Regulatory | N/A | Tier 1 | QL | 07/01/2020 |
| | | Requirement | | | | |
| Vivitrol Injection | Tier Change from Tier 3 to Tier 1 | Regulatory | N/A | Tier 1 | QL | 07/01/2020 |
| | | Requirement | | | | |
| Nicotrol Inhaler | New Addition | Regulatory | N/A | Tier 1 | QL | 07/01/2020 |
| | | Requirement | | | | |
| Nicotrol Nasal Spray | New Addition | Regulatory | N/A | Tier 1 | QL | 07/01/2020 |
| | | Requirement | | | | |
| Ajovy Injection | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 07/01/2020 |
| Combigan Eye Drops | New Addition | New Addition | Brimonidine Eye | Tier 4 | LA, QL, ST | 07/01/2020 |
| | | | Drops or Timolol | | | |
| | | | Eye Drops | | | |
| Brilinta Tablets | New Addition | New Addition | Clopidogrel | Tier 4 | LA, QL, ST | 07/01/2020 |
| Cimzia Injection | New Addition | New Addition | N/A | Tier 5 | LA, QL, PA | 07/01/2020 |
| Horizant Tablets | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 07/01/2020 |
| Bydureon Injection | New Addition | New Addition | Trulicity | Tier 4 | LA, QL, ST | 07/01/2020 |
| Combipatch Transdermal | New Addition | New Addition | Estradiol/noreth- | Tier 4 | LA, QL, ST | 07/01/2020 |
| Patches | | | indrone Tablets, | | | |
| | | | Estradiol Patches | | | |
| | | | or Estradiol | | | |
| | | | Vaginal Cream | | | |
| Femring Vaginal Ring | New Addition | New Addition | Estradiol Vaginal | Tier 4 | LA, QL, ST | 07/01/2020 |
| | | | Cream | | | |
| Desvenlafaxine Tablets | New Addition | New Addition | N/A | Tier 2 | LA, QL, PA | 07/01/2020 |
| Clindamycin Vaginal | New Addition | New Addition | N/A | Tier 1 | QL | 07/01/2020 |

| Name of Affected Dur | Description of Change | Desses for Charge | | New | Destrictions | Effective |
|---|--|---|---|--------|--------------|------------|
| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | Tier | Restrictions | Date |
| Cream | | | | | | |
| Ezetimibe Tablets | New Addition | New Addition | N/A | Tier 1 | QL | 07/01/2020 |
| Farxiga Tablets | Step Therapy Restriction Removed | Clinical Reevaluation | N/A | N/A | LA, QL | 07/01/2020 |
| Insulin Aspart and Insulin Aspart/Insulin Aspart Protamine Mix Vials | New Generic for Novolog and Novolog Mix | New Generic | N/A | Tier 1 | QL | 04/01/2020 |
| Insulin Aspart and Insulin Aspart/Insulin Aspart Protamine Mix Pens and Cartridges | New Generic for Novolog and Novolog Mix | New Generic | N/A | Tier 2 | LA, QL | 04/01/2020 |
| Budesonide/Formoterol Inhalers | New Generic for Symbicort; Step Therapy Restriction Removed | New Generic; Clinical and Cost Reevaluation | N/A | Tier 2 | LA, QL | 04/01/2020 |
| Hydroxychloroquine Tablets | Quantity Limit Restriction Added | Clinical Reevaluation | N/A | N/A | LA, QL | 04/01/2020 |
| Chloroquine Tablets | Quantity Limit Restriction Added | Clinical Reevaluation | N/A | N/A | QL | 04/01/2020 |
| Kaletra Tablets and Oral Solution | Quantity Limit Restriction Added | Clinical Reevaluation | N/A | N/A | LA, QL | 04/01/2020 |
| Pyrimethamine Tablets | New generic for Daraprim | New Generic | N/A | Tier 2 | LA | 04/01/2020 |
| Glycopyrrolate Tablets | New Addition | New Addition | N/A | Tier 1 | | 04/01/2020 |
| Dulera Inhalers | New Addition | New Addition | Fluticasone/ Salmeterol and Budesonide/ Formoterol | Tier 4 | LA, QL, ST | 04/01/2020 |
| Tirosint Capsules and Oral Solution | New Addition | New Addition | Levothyroxine | Tier 4 | LA, QL, ST | 04/01/2020 |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective Date |
|---------------------------|-----------------------|-------------------|--------------------|-------------|--------------|-------------------|
| Fiasp Vials, Pens and | New Addition | New Addition | Insulin Aspart and | Tier 4 | LA, QL, ST | 04/01/2020 |
| Cartridges | | | Insulin Lispro | | | |
| Nucynta ER Tablets | New Addition | New Addition | Oxycodone ER, | Tier 4 | LA, QL, ST | 04/01/2020 |
| | | | Morphine ER, | | | |
| | | | Fentanyl, or | | | |
| | | | Methadone | | | |
| Envarsus XR Tablets | New Addition | New Addition | Tacrolimus | Tier 5 | LA, ST | 04/01/2020 |
| Corlanor Tablets and Oral | New Addition | New Addition | Atenolol, | Tier 4 | LA, QL, ST | 04/01/2020 |
| Solution | | | Carvedilol, | | | |
| | | | Labetalol, | | | |
| | | | Metoprolol, | | | |
| | | | Nadolol, Pindolol, | | | |
| | | | Propranolol or | | | |
| | | | Sotalol | | | |
| Trelegy Ellipta Inhalers | New Addition | New Addition | Two of the | Tier 4 | LA, QL, ST | 04/01/2020 |
| | | | following: | | | |
| | | | Fluticasone/ | | | |
| | | | Salmeterol | | | |
| | | | Inhaler; | | | |
| | | | Budesonide/ | | | |
| | | | Formoterol | | | |
| | | | Inhaler; Spiriva | | | |
| | | | Inhaler | | | |
| Eliquis Tablets | New Addition | New Addition | Xarelto | Tier 4 | LA, QL, ST | 04/01/2020 |
| Emgality Pens and | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 04/01/2020 |
| Syringes | | | | | | |
| Invega Sustenna Syringes | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 04/01/2020 |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective Date |
|---|-------------------------------------|-----------------------------------|---|-------------|--------------|-------------------|
| Abilify Maintena Vials and Syringes | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 04/01/2020 |
| Stelara Vials and Syringes | New Addition | New Addition | N/A | Tier 5 | LA, PA | 04/01/2020 |
| Lansoprazole Capsules and Orally-Disintegrating Tablets | New Addition | New Addition | N/A | Tier 2 | LA, QL | 04/01/2020 |
| Lupron Depot and Depot- Ped Syringe Kits | New Addition | New Addition | N/A | Tier 4 | LA, PA | 04/01/2020 |
| Breo Ellipta Inhalers | New Addition | New Addition | Fluticasone/ Salmeterol and Budesonide/ Formoterol | Tier 4 | LA, QL, ST | 04/01/2020 |
| Oxycodone ER Tablets | Step Therapy Restriction Removed | Clinical and Cost Reevaluation | N/A | N/A | LA, QL | 04/01/2020 |
| Acitretin Capsules | Step Therapy Restriction Removed | Clinical and Cost Reevaluation | N/A | N/A | LA | 04/01/2020 |
| Ozempic Pens | New Addition | New Addition | Trulicity | Tier 4 | LA, QL, ST | 04/01/2020 |
| Estrogel Transdermal Gel | New Addition | New Addition | Estradiol Tablets, Patches or Vaginal Cream | Tier 4 | LA, QL, ST | 04/01/2020 |
| Baqsimi Nasal Spray | New Addition | New Addition | Glucagon Injection | Tier 4 | LA, QL, ST | 04/01/2020 |
| Cequa Eye Drops | New Addition | New Addition | Restasis | Tier 4 | LA, QL, ST | 04/01/2020 |
| Victoza Pens | Step Therapy Restriction Removed | Clinical and Cost Reevaluation | N/A | N/A | LA, QL | 04/01/2020 |
| Trulicity Pens | New Addition | New Addition | N/A | Tier 4 | LA, QL | 04/01/2020 |
| Toujeo and Toujeo Max Pens | New Addition | New Addition | Lantus and Levemir | Tier 4 | LA, QL, ST | 04/01/2020 |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective Date |
|--------------------------|------------------------------------|-------------------|------------------|-------------|--------------|-------------------|
| Dovato Tablets | New Addition | New Addition | N/A | Tier 5 | LA, QL | 04/01/2020 |
| Armour Thyroid Tablets | New Addition | New Addition | Levothyroxine | Tier 4 | LA, QL, ST | 04/01/2020 |
| Neulasta Syringes | New Addition | New Addition | N/A | Tier 5 | LA, QL | 04/01/2020 |
| Dexilant Capsules | Prior Authorization Restriction | Clinical and Cost | Omeprazole, | N/A | LA, QL, ST | 04/01/2020 |
| | Removed; Step Therapy | Reevaluation | Pantoprazole and | | | |
| | Restriction Added | | Esomeprazole | | | |
| Qbrexza Towelettes | Prior Authorization Restriction | Clinical and Cost | Drysol | N/A | LA, QL, ST | 04/01/2020 |
| | Removed; Step Therapy | Reevaluation | | | | |
| | Restriction Added | | | | | |
| Mydayis Capsules | Prior Authorization Restriction | Clinical and Cost | Amphetamine and | N/A | LA, QL, ST | 04/01/2020 |
| | Removed; Step Therapy | Reevaluation | Methylphenidate | | | |
| | Restriction Added | | Products | | | |
| Adacel/Boostrix | New Addition | New Addition | N/A | Tier 1 | | 01/01/2020 |
| Adolescent and Adult | | | | | | |
| TDAP Vaccines | | | | | | |
| Daptacel/Infanrix | New Addition | New Addition | N/A | Tier 1 | | 01/01/2020 |
| Pediatric TDAP Vaccines | | | | | | |
| Potassium Citrate | New Addition | New Addition | N/A | Tier 2 | LA | 01/01/2020 |
| Extended-Release Tablets | | | | | | |
| Pregabalin Capsules | Step Therapy Restriction | Clinical and Cost | N/A | N/A | LA, QL | 01/01/2020 |
| | Removed | Reevaluation | | | | |
| Esomeprazole Capsules | Step Therapy Restriction | Clinical and Cost | N/A | N/A | LA, QL | 01/01/2020 |
| | Removed | Reevaluation | | | | |
| Etonogestrel/Ethinyl | New Generic for Nuvaring | New Generic | N/A | N/A | | 01/01/2020 |
| Estradiol Vaginal Ring | | | | | | |
| Buprenorphine | Tier Change from Tier 2 to Tier 1; | Regulatory | N/A | Tier 1 | QL | 01/01/2020 |
| Sublingual Tablets | Limited Access Restriction | Requirement | | | | |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective Date |
|-------------------------|------------------------------------|-------------------|-------------------|-------------|--------------|-------------------|
| | Removed | | | | | |
| Buprenorphine/Naloxone | Tier Change from Tier 2 to Tier 1; | Regulatory | N/A | Tier 1 | QL | 01/01/2020 |
| Sublingual Films and | Limited Access Restriction | Requirement | | | | |
| Tablets | Removed | | | | | |
| Vivitrol Suspension for | Tier Change from Tier 4 to Tier 3; | Regulatory | N/A | Tier 3 | QL | 01/01/2020 |
| Injection | Limited Access Restriction | Requirement | | | | |
| | Removed | | | | | |
| Trikafta Tablets | New Addition | New Addition | N/A | Tier 5 | LA, QL, PA | 01/01/2020 |
| Simponi Autoinjectors | New Addition | New Addition | N/A | Tier 5 | LA, QL, PA | 01/01/2020 |
| Fetzima Capsules | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 01/01/2020 |
| Mydayis Capsules | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 01/01/2020 |
| Dexilant Capsules | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 01/01/2020 |
| Trintellix Tablets | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 01/01/2020 |
| Estring Vaginal Ring | New Addition | New Addition | Estradiol Vaginal | Tier 4 | LA, QL, ST | 01/01/2020 |
| | | | Cream | | | |
| Synagis Vials | New Addition | New Addition | N/A | Tier 5 | LA, PA | 01/01/2020 |
| Cambia Powder Packets | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 01/01/2020 |
| Qbrexza Towelettes | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 01/01/2020 |
| Cosentyx Syringes and | New Addition | New Addition | N/A | Tier 5 | LA, QL, PA | 01/01/2020 |
| Pens | | | | | | |
| Famotidine Tablets | New Addition | New Addition | N/A | Tier 1 | | 01/01/2020 |
| Biktarvy Tablets | New Addition | New Addition | Triumeq, | Tier 5 | LA, QL, ST | 01/01/2020 |
| | | | Tivicay/Descovy, | | | |
| | | | Isentress/Descovy | | | |
| Myrbetriq Tablets | New Addition | New Addition | Oxybutynin, | Tier 4 | LA, QL, ST | 01/01/2020 |
| | | | Tolterodine | | | |
| Banzel Tablets and | New Addition | New Addition | Lamotrigine, | Tier 4 | LA, QL, ST | 01/01/2020 |

| Name of Affected Drug | Description of Change | Descen for Change | Alternetive Drug | New | Restrictions | Effective |
|--------------------------|-------------------------------|-------------------|------------------|--------|--------------|------------|
| Name of Affected Drug | | Reason for Change | Alternative Drug | Tier | Restrictions | Date |
| Suspension | | | Topiramate, | | | |
| | | | Clobazam | | | |
| Eucrisa Ointment | New Addition | New Addition | Topical | Tier 4 | LA, QL, ST | 01/01/2020 |
| | | | Corticosteroids, | | | |
| | | | Tacrolimus | | | |
| | | | Ointment | | | |
| Amitiza Capsules | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 01/01/2020 |
| Jakafi Tablets | New Addition | New Addition | N/A | Tier 5 | LA, QL, PA | 01/01/2020 |
| Valchlor Gel | New Addition | New Addition | N/A | Tier 5 | LA, QL, PA | 01/01/2020 |
| Orencia Syringes | New Addition | New Addition | N/A | Tier 5 | LA, QL, PA | 01/01/2020 |
| Jynarque Tablets | New Addition | New Addition | N/A | Tier 5 | LA, QL, PA | 01/01/2020 |
| Rubraca Tablets | New Addition | New Addition | N/A | Tier 5 | LA, QL, PA | 01/01/2020 |
| Cuvposa Solution | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 01/01/2020 |
| Linzess Capsules | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 01/01/2020 |
| Xyrem Solution | New Addition | New Addition | N/A | Tier 5 | LA, QL, PA | 01/01/2020 |
| Viibryd Tablets | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 01/01/2020 |
| Gilenya Capsules | New Addition | New Addition | N/A | Tier 5 | LA, QL, PA | 01/01/2020 |
| Tobi Podhaler | New Addition | New Addition | N/A | Tier 5 | LA, QL, PA | 01/01/2020 |
| Epidiolex Solution | New Addition | New Addition | N/A | Tier 5 | LA, QL, PA | 01/01/2020 |
| Vraylar Capsules | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 01/01/2020 |
| Orkambi Tablets and | New Addition | New Addition | N/A | Tier 5 | LA, QL, PA | 01/01/2020 |
| Granule Packs | | | | | | |
| Kalydeco Tablets and | New Addition | New Addition | N/A | Tier 5 | LA, QL, PA | 01/01/2020 |
| Granule Packs | | | | | | |
| Insulin Lispro Vials and | New Generic for Humalog Vials | New Generic | | Tier 1 | QL | 10/01/2019 |
| Pens | and KwikPens | | | | | |
| Dupixent Syringes | New Addition | New Addition | | Tier 5 | LA, QL, PA | 10/01/2019 |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective Date |
|-----------------------|-----------------------|-------------------|-------------------|-------------|--------------|-------------------|
| Otezla Tablets | New Addition | New Addition | | Tier 5 | LA, QL, PA | 10/01/2019 |
| Farxiga Tablets | New Addition | New Addition | One Formulary | | LA, QL, ST | 10/01/2019 |
| | | | Diabetic | | | |
| | | | Medication | | | |
| Belsomra Tablets | New Addition | New Addition | Two of the | Tier 4 | LA, QL, ST | 10/01/2019 |
| | | | following: | | | |
| | | | Eszopiclone, | | | |
| | | | Zolpidem, | | | |
| | | | Temazepam, | | | |
| | | | Trazodone | | | |
| Latuda Tablets | New Addition | New Addition | | Tier 4 | LA, QL, PA | 10/01/2019 |
| Aimovig Autoinjectors | New Addition | New Addition | | Tier 4 | LA, QL, PA | 10/01/2019 |
| Xiidra Ophthalmic | New Addition | New Addition | Restasis | Tier 4 | LA, QL, ST | 10/01/2019 |
| Solution | | | | | | |
| Vimpat Tablets | New Addition | New Addition | Two of the | Tier 4 | LA, QL, ST | 10/01/2019 |
| | | | following: | | | |
| | | | Carbamazepine, | | | |
| | | | Divalproex sodium | | | |
| | | | or valproic acid, | | | |
| | | | Felbamate, | | | |
| | | | Gabapentin, | | | |
| | | | Lamotrigine, | | | |
| | | | Levetiracetam, | | | |
| | | | Oxcarbazepine, | | | |
| | | | Phenobarbital, | | | |
| | | | Phenytoin, | | | |
| | | | Pregabalin | | | |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New | Restrictions | Effective |
|-------------------------|--------------------------------|-------------------|------------------|--------|--------------|------------|
| Name of Anected Drug | Description of change | Reason for change | Alternative Drug | Tier | Restrictions | Date |
| | | | (Lyrica), | | | |
| | | | Topiramate, | | | |
| | | | Zonisamide | | | |
| Erythromycin 333mg | New Generic for Ery-Tab 333 mg | New Generic | | Tier 1 | | 10/01/2019 |
| Tablets | Tablets | | | | | |
| Pregabalin Capsules | New Generic for Lyrica | New Generic | Gabapentin or | Tier 2 | LA, QL, ST | 10/01/2019 |
| | | | Duloxetine | | | |
| Symbicort Inhalers | New Addition | New Addition | Advair Diskus or | Tier 4 | LA, QL, ST | 07/01/2019 |
| | | | Advair HFA | | | |
| Clobazam Tablets and | New Addition | New Addition | Lamotrigine and | Tier 2 | LA, QL, ST | 07/01/2019 |
| Suspension | | | Topiramate | | | |
| Rizatriptan Tablets and | New Addition | New Addition | N/A | Tier 2 | LA, QL | 07/01/2019 |
| Oral Disintegrating | | | | | | |
| Tablets | | | | | | |
| Invokana Tablets | New Addition | New Addition | One Formulary | Tier 4 | LA, QL, ST | 07/01/2019 |
| | | | Diabetic | | | |
| | | | Medication | | | |
| Paliperidone Extended- | New Addition | New Addition | N/A | Tier 2 | LA, QL, PA | 07/01/2019 |
| Release Tablets | | | | | | |
| Dexmethylphenidate | New Addition | New Addition | N/A | Tier 2 | LA, QL | 07/01/2019 |
| Tablets and Extended- | | | | | | |
| Release Capsules | | | | | | |
| Cefixime 400 mg | New Generic for Suprax 400 mg | New Generic | N/A | Tier 1 | QL | 07/01/2019 |
| Capsules | Capsules | | | | | |
| Eletriptan Tablets | Step Therapy Restriction | Clinical and Cost | N/A | N/A | LA, QL | 07/01/2019 |
| | Removed | Reevaluation | | | | |
| First-Omeprazole | Deletion | Regulatory | N/A | N/A | | 07/01/2019 |

| Name of Affected Drug | Description of Change | Desses for Change | | New | Destrictions | Effective |
|--------------------------|---------------------------------|-----------------------|------------------|--------|--------------|------------|
| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | Tier | Restrictions | Date |
| Suspension | | Requirement | | | | |
| First-Mouthwash BLM | Deletion | Regulatory | N/A | N/A | | 07/01/2019 |
| Liquid | | Requirement | | | | |
| Sevelemer Carbonate 800 | New Addition | New Addition | N/A | Tier 2 | LA, QL | 04/01/2019 |
| mg Tablets | | | | | | |
| Sevelemer Hydrochloride | New Addition | New Addition | N/A | Tier 2 | LA, QL | 04/01/2019 |
| 800 mg Tablets | | | | | | |
| FreeStyle Libre 14-Day | New Addition | New Addition | N/A | Tier 2 | LA, QL, PA | 04/01/2019 |
| Reader and Sensor | | | | | | |
| Fluticasone/Salmeterol | New Generics for Advair Diskus | New Generic | N/A | Tier 1 | QL | 04/01/2019 |
| and Wixela-Inhub Disk | | | | | | |
| Inhalers | | | | | | |
| Buprenorphine/Naloxone | New Generics for Suboxone | New Generic | N/A | Tier 2 | LA, QL | 04/01/2019 |
| 2 mg/0.5 mg, 4 mg/1 mg, | 2 mg/0.5 mg, 4 mg/1 mg, and | | | | | |
| and 12 mg/3 mg Films | 12 mg/3 mg Films | | | | | |
| Albuterol Sulfate 90 mcg | New Generic | New Generic; | N/A | Tier 1 | QL | 04/01/2019 |
| Metered Dose Inhaler | | Therapeutic | | | | |
| | | Alternative to ProAir | | | | |
| | | HFA and Ventolin | | | | |
| | | HFA | | | | |
| Ledipasvir/Sofosbuvir | New Generic for Harvoni | New Generic | N/A | Tier 4 | LA, QL, PA | 01/01/2019 |
| Tablets | | | | | | |
| Sofosbuvir/Velpatasvir | New Generic for Epclusa | New Generic | N/A | Tier 4 | LA, QL, PA | 01/01/2019 |
| Tablets | | | | | | |
| Albendazole Tablets | New Generic for Albenza | New Generic | N/A | Tier 1 | | 01/01/2019 |
| Estradiol Valerate Vials | New Addition | New Addition | N/A | Tier 1 | | 01/01/2019 |
| Lyrica | Prior Authorization Restriction | Clinical and Cost | Gabapentin or | N/A | LA, QL, ST | 01/01/2019 |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New | Restrictions | Effective |
|--------------------------|------------------------------------|-------------------|------------------|--------|--------------|------------|
| | Description of change | Reason for change | Alternative Drug | Tier | Restrictions | Date |
| | Removed; Step Therapy | Reevaluation | Duloxetine | | | |
| | Restriction Added | | | | | |
| Atomoxetine Capsules | New Addition | New Addition | N/A | Tier 2 | LA, QL | 07/01/2018 |
| Fondaparinux Syringes | New Addition | New Addition | N/A | Tier 4 | LA, QL | 07/01/2018 |
| Buprenorphine/Naloxone | New Generic for Suboxone | New Generic | N/A | Tier 2 | LA, QL | 07/01/2018 |
| Film 8 mg/2 mg Film | 8 mg/2mg Film | | | | | |
| Praziquantel Tablets | New Generic for Biltricide | New Generic | N/A | Tier 2 | LA | 07/01/2018 |
| Atovaquone/Proguanil | Tier Change from Tier 2 to Tier 1; | Cost Reevaluation | N/A | Tier 1 | QL | 07/01/2018 |
| Tablets | Quantity Limit Restriction Added | | | | | |
| Ritonavir Tablets | New Generic for Norvir | New Generic | N/A | Tier 2 | LA | 04/01/2018 |
| Tacrolimus Capsules | New Addition | New Addition | N/A | Tier 2 | LA | 04/01/2018 |
| Tradjenta Tablets | New Addition | New Addition | N/A | Tier 4 | LA, QL | 04/01/2018 |
| Jentadueto Tablets | New Addition | New Addition | N/A | Tier 4 | LA, QL | 04/01/2018 |
| Narcan Nasal Spray | New Addition | New Addition | N/A | Tier 3 | QL | 04/01/2018 |
| Buprenorphine | New Addition | New Addition | N/A | Tier 2 | LA, QL | 04/01/2018 |
| Sublingual Tablets | | | | | | |
| Estradiol Vaginal Cream | New Addition | New Addition | N/A | Tier 1 | QL | 04/01/2018 |
| Efavirenz Capsules | New Generic for Sustiva | New Generic | N/A | Tier 2 | LA | 04/01/2018 |
| Tenofovir Disoproxil | New Generic for Viread | New Generic | N/A | Tier 2 | LA | 04/01/2018 |
| Fumarate Tablets | | | | | | |
| Atazanavir Capsules | New Generic for Reyataz | New Generic | N/A | Tier 2 | LA | 04/01/2018 |
| Aripiprazole Tablets | Step Therapy Restriction | Clinical and Cost | N/A | N/A | LA, QL | 01/01/2018 |
| | Removed | Reevaluation | | | | |
| Metformin Extended- | Tier Change from Tier 1 to Tier 2; | Cost Reevaluation | Metformin | Tier 2 | LA | 01/01/2018 |
| Release Tablets (Generic | Limited Access Restriction Added | | Extended-Release | | | |
| for Fortamet) | | | (Generic for | | | |
| | | | Glucophage XR) | | | |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective Date |
|---------------------------|---|---------------------------------------|---|-------------|--------------|-------------------|
| Lyrica Capsules | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 01/01/2018 |
| Oxycodone Extended- | New Addition | New Addition | One Formulary | Tier 2 | LA, QL, ST | 01/01/2018 |
| Release Tablets | | | Long-Acting Opioid | | | |
| Victoza Pens | New Addition | New Addition | One Formulary Diabetic Medication | Tier 4 | LA, QL, ST | 01/01/2018 |
| Priftin Tablets | New Addition | New Addition | N/A | Tier 4 | LA | 01/01/2018 |
| Abacavir Oral Solution | New Generic Available for Ziagen | New Generic | N/A | Tier 2 | LA | 10/01/2017 |
| Eletriptan | New Generic Available for Relpax | New Generic | Sumatriptan and zolmitriptan | Tier 2 | LA, QL, ST | 10/01/2017 |
| Imiquimod | Tier Change from Tier 2 to Tier 1; Limited Access Restriction Removed | Clinical and Cost Reevaluation | N/A | Tier 1 | | 10/01/2017 |
| Enoxaparin | Tier Change from Tier 3 to Tier 2; Limited Access Restriction Removed | Clinical and Cost Reevaluation | N/A | Tier 2 | QL | 10/01/2017 |
| Mavyret | New Addition | New Addition | N/A | Tier 4 | LA, QL, PA | 10/01/2017 |
| Entresto Tablets | New Addition | New Addition | N/A | Tier 3 | LA, QL | 07/01/2017 |
| Risperdal Consta Syringes | New Addition | New Addition | Oral Risperidone | Tier 3 | LA, QL, ST | 07/01/2017 |
| Jardiance Tablets | New Addition | New Addition | One Formulary Diabetic Medication | Tier 3 | LA, QL, ST | 07/01/2017 |
| Codeine Products | Age Restriction Updated to 12 Years and Older | FDA Safety Warning Labeling Change | N/A | N/A | Age, QL | 07/01/2017 |
| Tramadol Tablets | Age Restriction Added for 12 Years and Older | FDA Safety Warning Labeling Change | N/A | N/A | Age, QL | 07/01/2017 |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective Date |
|---------------------------|--|-----------------------|------------------|-------------|--------------|-------------------|
| Ondansetron Tablets and | Quantity Limit Increased from 30 | Clinical and Cost | N/A | N/A | QL | 07/01/2017 |
| Oral-Disintegrating | Tablets Per 30 Days to 90 Tablets | Reevaluation | | | | |
| Tablets | Per 30 Days | | | | | |
| Norvir | Tier Change from Tier 4 to Tier 3 | Clinical Reevaluation | N/A | Tier 3 | LA | 07/01/2017 |
| Vivitrol Vials | Prior Authorization Restriction Removed | Clinical Reevaluation | N/A | Tier 3 | LA, QL | 07/01/2017 |
| Antipyrine/Benzocaine | Tier Change from Tier 1 to Tier 2; | Regulatory | N/A | Tier 2 | LA | 07/01/2017 |
| Otic Solution | Limited Access Restriction Added | Requirement | | | | |
| Atropine Ophthalmic | | | | | | |
| Solution | | | | | | |
| Cytra-K Crystals and Oral | | | | | | |
| Solution | | | | | | |
| Donnatal Elixir and | | | | | | |
| Tablets | | | | | | |
| Esterified Estrogens/ | | | | | | |
| Methyltestosterone | | | | | | |
| Tablets | | | | | | |
| Hydrocortisone/ | | | | | | |
| Pramoxine Rectal Cream | | | | | | |
| Phenazopyridine Tablets | | | | | | |
| Tacrolimus Ointment | New Addition | New Addition | Topical | Tier 2 | LA, QL, ST | 04/01/2017 |
| | | | Corticosteroids | | | |
| Vyvanse Capsules | New Addition | New Addition | Amphetamine | Tier 3 | LA, QL, ST | 04/01/2017 |
| | | | Salts and | or 4 | | |
| | | | Methylphenidate | | | |
| Xarelto 20 mg Tablets | Step Therapy Restriction | Clinical and Cost | N/A | N/A | LA, QL | 04/01/2017 |
| | Removed | Reevaluation | | | | |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective |
|--------------------------|----------------------------------|-----------------------|------------------|-------------|--------------|------------|
| | | | | | | Date |
| Venlafaxine Extended- | Quantity Limit Restriction | Clinical Reevaluation | N/A | N/A | QL | 04/01/2017 |
| Release Capsules | Increased | | | | | |
| Fenofibrate Tablets | Step Therapy Restriction | Clinical and Cost | N/A | N/A | QL | 04/01/2017 |
| | Removed | Reevaluation | | | | |
| Doxycycline Capsules and | Quantity Limit Restriction | Cost Reevaluation | N/A | N/A | QL | 04/01/2017 |
| Tablets | Increased | | | | | |
| Duloxetine Capsules | Step Therapy Restriction | Clinical and Cost | N/A | Tier 1 | QL | 04/01/2017 |
| | Removed and Tier Change from | Reevaluation | | | | |
| | Tier 2 to Tier 1 | | | | | |
| Aranesp Syringes and | Prior Authorization Restriction | Clinical Reevaluation | N/A | N/A | LA | 01/01/2017 |
| Vials | Removed | | | | | |
| Leukine Syringes and | Prior Authorization Restriction | Clinical Reevaluation | N/A | N/A | LA | 01/01/2017 |
| Vials | Removed | | | | | |
| Neupogen Syringes and | Prior Authorization Restriction | Clinical Reevaluation | N/A | N/A | LA | 01/01/2017 |
| Vials | Removed | | | | | |
| Epinephrine Auto- | New Generic Available for Epipen | New Generic | N/A | Tier 1 | QL | 01/01/2017 |
| Injectors | and Epipen Jr | | | | | |
| Descovy Tablets | New Addition | New Addition | N/A | Tier 3 | LA | 01/01/2017 |
| Genvoya Tablets | New Addition | New Addition | N/A | Tier 3 | LA | 01/01/2017 |
| Odefsey Tablets | New Addition | New Addition | N/A | Tier 3 | LA | 01/01/2017 |
| Vemlidy Tablets | New Addition | New Addition | N/A | Tier 3 | LA | 01/01/2017 |
| Vivitrol Vials | New Addition | New Addition | N/A | Tier 3 | LA, QL, PA | 01/01/2017 |
| Oseltamivir Capsules | New Generic Available for | New Generic | N/A | Tier 1 | QL | 01/01/2017 |
| | Tamiflu | | | | | |
| Abacavir/Lamivudine | New Generic Available for | New Generic | N/A | Tier 2 | LA | 01/01/2017 |
| Tablets | Epzicom | | | | | |
| Aripiprazole Tablets | Prior Authorization Restriction | Clinical Reevaluation | Clozapine, | N/A | LA, QL, PA | 01/01/2017 |

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective |
|-----------------------|-----------------------------------|-----------------------|-------------------|-------------|--------------|------------|
| | | | | | | Date |
| | Removed; Step Therapy | | Olanzapine, | | | |
| | Restriction Added | | Quetipaine, | | | |
| | | | Risperidone, | | | |
| | | | Ziprasidone | | | |
| Lidocaine 5% Ointment | Tier Change from Tier 1 to Tier 2 | Cost Reevaluation | Lidocaine 4% | Tier 2 | LA, QL | 01/01/2017 |
| | and Limited Access and Quantity | | Cream | | | |
| | Limit Restrictions Added | | | | | |
| Sovaldi Tablets | Deletion | Cost Reevaluation | Epclusa, Harvoni, | N/A | N/A | 01/01/2017 |
| | | | Zepatier | | | |
| Epclusa Tablets | New Addition | New Addition | N/A | Tier 4 | LA, PA, QL | 10/01/2016 |
| Zepatier Tablets | New Addition | New Addition | N/A | Tier 4 | LA, PA, QL | 10/01/2016 |
| Mesalamine Delayed- | New Generic Available for Asacol | New Generic | N/A | N/A | | 10/01/2016 |
| Release Tablets | HD | | | | | |
| Colchicine Tablets | New Addition | New Addition | N/A | Tier 2 | LA, QL, ST | 10/01/2016 |
| Guanfacine Extended- | Step Therapy Restriction | Clinical Reevaluation | N/A | N/A | LA, QL | 10/01/2016 |
| Release Tablets | Removed | | | | | |
| Acitretin Capsules | Prior Authorization Restriction | Clinical Reevaluation | Methotrexate | N/A | LA, ST | 10/01/2016 |
| | Removed; Step Therapy | | | | | |
| | Restriction Added | | | | | |
| Rosuvastatin Tablets | New Generic Available for | New Generic | N/A | Tier 2 | LA, QL | 07/01/2016 |
| | Crestor | | | | | |
| Modafinil Tablets | New Addition | New Addition | N/A | Tier 2 | QL | 07/01/2016 |
| Complera Tablets | New Addition | New Addition | N/A | Tier 4 | LA | 07/01/2016 |
| Celecoxib Capsules | Step Therapy Restriction | Clinical Reevaluation | N/A | N/A | QL | 07/01/2016 |
| | Removed | | | | | |
| Diclofenac Gel | New Generic Available for | New Generic | N/A | Tier 1 | QL | 07/01/2016 |
| | Voltaren Gel | | | | | |

Created: 07/01/2016 27 Updated: 07/01/2022

| Name of Affected Drug | Description of Change | Reason for Change | Alternative Drug | New Tier | Restrictions | Effective Date |
|-----------------------|-------------------------|-----------------------|------------------|-------------|--------------|-------------------|
| Levitra Tablets | Age Restriction Removed | Clinical Reevaluation | N/A | N/A | QL | 07/01/2016 |